期刊論文1. | 朱美虹(20121000)。由Astra Zeneca Pharmaceuticals LP v. Apotex Corp.案看美國專利連結(Patent Linkage)制度對學名藥廠的影響。萬國法律,185,89-97。 延伸查詢 |
2. | Weiswasser, Elizabeth Stotland、Danzis, Scott D.(2003)。The Hatch-Waxman Act: History, Structure, and Legacy。Antitrust Law Journal,71(2),585-608。 |
3. | 李素華(20161200)。我國藥品專利保護之現況與未來--從專利連結制度之研擬談起。智慧財產權月刊,216,5-28。 延伸查詢 |
4. | 李素華、吳全峰(20161100)。初探藥事法增訂專利連結專章之立法芻議。月旦法學,258,163-177。 延伸查詢 |
5. | 朱浩筠(20160900)。美國專利舉發制度及其相關爭議問題簡介以多方複審(IPR)案件為中心。智慧財產權月刊,213,5-25。 延伸查詢 |
6. | Vishnubhakat, Saurabh、Rai, Arti K.、Kesan, Jay P.(20160210)。Strategic Decision Making in Dual PTAB and District Court Proceedings。Berkeley Technology Law Journal,31(1),45-116。 |
7. | 楊智傑、黃婷翊(20161000)。美國專利複審程序及Cuozzo Speed Technologies, LLC v. Lee案。專利師,27,18-57。 延伸查詢 |
8. | 李素華(20160100)。民事法院自為判斷專利有效性與加速解決紛爭之迷思--從最高法院一○四年度臺上字第四○七號民事判決談起。月旦裁判時報,43,31-43。 延伸查詢 |
9. | 張哲倫(20150400)。專利連結之歷史、緣由及其政策功能。智慧財產權月刊,196,5-19。 延伸查詢 |
10. | Hemphill, C. Scott、Lemley, Mark A.(2011)。Earning Exclusivity: Generic Drug Incentives and the Hatch-Waxman Act。Antitrust Law Journal,77,947-952。 |
11. | 沈宗倫(20180700)。簡評我國專利連結制度之相關立法--以藥事法之解釋適用為中心。月旦法學,278,165-177。 延伸查詢 |
12. | 侯春岑、林宗緯(20180200)。臺灣專利連結制度簡介。萬國法律,217,33-43。 延伸查詢 |
13. | 滕沛倫、宋皇志(20170300)。我國真有引進專利連結制度之必要嗎?--對藥事法與專利法修正草案之評析。智慧財產評論,14(2),43-78。 延伸查詢 |
14. | 陳在方(20171200)。美國專利紛爭解決之關鍵性變革--論美國專利複審程序的結構功能分析與實施成效。交大法學評論,2,1-62。 延伸查詢 |
15. | 朱淑尹(20150400)。美國專利連結制度中專利登錄的介紹與探討。智慧財產權月刊,196,20-33。 延伸查詢 |
16. | Xu, Nora(2017)。AIA Proceedings: A Prescription for Accelerating the Availability of Generic Drugs。Emory Law Journal,66(4),1007-1066。 |
17. | Wasserman, Melissa F.(2013)。The Changing Guard of Patent Law: Chevron Deference for the PTO。William and Mary Law Review,54(6),1959-2019。 |
18. | Sturiale, Jennifer E.(2017)。Hatch-Waxman Patent Litigation and Interpartesreview: A New Sort of Competition。Alabama Law Review,69。 |
19. | 顏雅倫、張濱璿、廖國雄(20170700)。藥品專利連結制度與競爭法規範之研究--以逆向給付協議為中心。公平交易季刊,25(3),75-126。 延伸查詢 |
20. | 黃慧嫺(20060700)。淺析美國藥品上市審查程序之專利連結機制及其實施對我國可能產生之影響。科技法律透析,18(7),2-8。 延伸查詢 |
21. | 黃慧嫺(20060600)。淺析美國藥品上市審查程序之專利連結機制及其實施對我國可能產生之影響。科技法律透析,18(6),2-7。 延伸查詢 |
22. | 林宗緯(20150600)。Hatch‐Waxman法案及我國既有法規之比較--對我國引進專利連結制度之建議。萬國法律,201,47-57。 延伸查詢 |
23. | 張銘晃(20130600)。專利有效性判斷歧異之再審爭議--以臺灣、日本法制比較為中心。智慧財產權月刊,174,84-121。 延伸查詢 |
24. | 楊智傑(20180900)。美國與臺灣專利民事侵權訴訟爭點效之發展與爭議--兼論臺灣專利無效雙軌制之困境。交大法學評論,3,97-158。 延伸查詢 |
25. | Choe, Jeong Yeol、Yoon, Kyung Ae、Lee, Samuel(2015)。Korea: The New First Battleground for the High Stakes Poker Game of Pharmaceutical Patent Litigation。Pharmaceutical Patent Analyst,4(6),409-413。 |
26. | Consilvio, Mark、Stroud, Jonathan R. K.(2013)。Unraveling the USPTO's Tangled Web: An Empirical Analysis of the Complex World of Post-Issuance Patent Proceedings。Journal of Intellectual Property Law,21(1),33-72。 |
27. | Kelly, Colleen(2003)。The Balance Between Innovation and Competition: The Hatch-Waxman Act, the 2003 Amendments, and Beyond。Food and Drug Law Journal,66(3),417-478。 |
28. | Kesselheim, Aaron S.、Darrowa, Jonathan J.(2015)。Hatch-Waxman Turns 30: Do We Need a Re-Designed Approach for the Modern Era?。Yale Journal of Health Policy, Law, and Ethics,15(2),293-347。 |
29. | Kim, Sung San(2015)。A Comparative Analysis of the Legal Framework and Case Law on Reverse Payment Settlement Agreement in the United States and South Korea。Journal of International Law and Business,35(2),377-411。 |
30. | Marenberg, Barry J.(2005)。FDA Provides Additional Guidance on 30-Month Stays--Multiple 30-Month Stays Still Possible。Biotechnology Law Report,24(1),7-9。 |
31. | O'Byrne Stephanie E.(2015)。IPRs and ANDA Litigation: All a Matter of Timing。FED. LAW.,62。 |
32. | Shepherd, Joanna(2016)。Disrupting the Balance: The Conflict Between Hatch-Waxman and Inter Partes Review。NYU Journal of Intellectual Property & Entertainment Law,6。 |
33. | 王立達、陳蔚奇(20101200)。學名藥上市審查之專利連結制度:從美國經驗檢證其存立基礎與制度設計。國立臺灣大學法學論叢,39(4),349-406。 延伸查詢 |
34. | 蕭郁溏、陳鋕雄(20150400)。從比較法觀點建構臺灣專利連結制度。萬國法律,200,92-110。 延伸查詢 |
其他1. | Divine, David A.。2013 Report of The Economic Survey,American Intellectual Property Law Ass'n。,http://www.patentinsurance.com/custdocs/2013aipla%20survey.pdf。 |
2. | (2018)。2018 Ministry of Food and Drug Safety White Paper,https://www.mfds.go.kr/eng/brd/m_60/view.do?seq=72621。 |
3. | (20180402)。A Statistical Analysis of Trial Requests Was Conducted After the Patent Linkage System of the Approval of Medicine and Medical Supplies Has Been in Operation for Three Year,http://www.pkkim.com/resources/new.asp?LetterNum=366&Page=2&bType=A。 |
4. | Davis, Ryan(20180824)。Patent Litigation In South Korea: What You Need To Know,https://www.law360.com/articles/1076694/。 |
5. | (20171128)。Generic Competition and Drug Prices,https://www.fda.gov/about-fda/center-drug-evaluation-and-research-cder/generic-competition-and-drug-prices。 |
6. | (20120131)。Drug Pricing: Research on Savings from Generic Drug Use,http://www.gao.gov/assets/590/588064.pdf,(GAO-12-371R)。 |
7. | Lee, Si Yul(20180526)。Patent Litigation in South Korea: Overview,https://uk.practicallaw.thomsonreuters.com/w-014-5857?transitionType= Default&contextData=(sc.Default)&firstPage=true&comp=pluk &bhcp=1#co_anchor_a725909。 |
8. | Solomon, Neal(20170808)。The Problem of Inter-Partes Review (IPR),https://www.ipwatchdog.com/2017/08/08/problem-inter-partes-review-ipr/id=86287/。 |
9. | Sun, Cho Young,Hyunsuk, Jin,Yoon & Yang LLC。Overview and Implication of the Drug Patent-Approval Linkage System in South Korean Regulation,http://global.practicallaw.com/3-557-9230#。 |
10. | Son, Min(20160126)。Korea: New Centralised Infringement Courts,http://www.managingip.com/Article/3521767/Korea-New-centralised-infringement-courts.html。 |
11. | Appeals & Trials,https://kipo.go.kr/en/HtmlApp?c=30300&catmenu=ek03_07_01。 |
12. | Generic Pharmaceutical Association(2015)。Generic Drug Savings in the U.S.,https://www.ncsl.org/documents/fsl/2015_Savings_Report_and_State_Savings.pdf。 |
13. | (20180926)。Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book),https://www.fda.gov/drugs/informationondrugs/ucm129662.htm。 |